Ontvang nu dagelijks onze kooptips!
word abonnee
sluiten ✕
Terug naar discussie overzicht
ProQR Therapeutics 2019
Volgen
Omschrijf het eens in het Nederlands?
Vertaling : het had zomaar proqr kunnen zijn
Zou PRQR nu bijna op een kantelpunt staan? Er zouden toch best snel weer koersen van rond de 10$ kunnen komen?
Nog wat Proqr gekocht. Heeft iemand een mening over Arbutus Biopharma Corporation (ABUS) ?
Ik had ABUS bijna voor $ 2,40 gekocht. Blij dat mij beperkt heb tot Arrowhead. De delivery bij RNAi blijkt cruciaal. ABUS moet nog aantonen dat haar Galnac methode gaat werken. Daarnaast is hun pijplijn erg mager. Als je er in gaat gok je op een bedrijfsovername. Ik beperk me liever tot clubs met bewezen technologie.
ABUS technology works as it is what ALNY uses in its approved drug Tom. in addition its pipeline is not thin. it has created at least 2 spin outs that leverage its technology .. Genvant i believe is one of them and it will have a growing pipeline.. ABUS is set to receive royalties once the products go to market ABUS however restricted itself internally to HBV which is a tough nut to crack. the potential is huge however. In its trial their drug sort of works. but there is more to work on to make it happen. ALso ABUS valuation is under cash. Abus is a turnaround story with a new CEO and a technology that works in the RNAi space. I am not invested in it but if compared to ARWR .. valuations, technology, potential , risks and all.. I personally would had preferred ABUS over ARWR. and some of the price targets show that ARWR could go up 50% where ABUS could go up 500% but better than ABUS is I think RGLS which will come out w its own HBV candidate this yr.
but back to Proqr ... I hope that phase1/2 results will provide it conditional approval in Europe at least. I looked if thats possible and found www.spglobal.com/marketintelligence/e... that based on the news, there is conditional approvals given... and phase 3 have to collaborate. If the phase1/2 results in September are as good or better than Proqr has reported to date... then........ and dont want to get too excited and pump here but.. have a good weekend y all
thnx Joel, for your input. The market is not awake yet for what regulus concerns. But i have put a 1000 euros in it, just to wait for further details. If it explodes, hurray, if not, a pity but not too much lost
RGLS is getting heavily accumulated, and in the coming months its supposed to have the following catalysts 1) get 20mill from Sanofi for this continuing the licensed program. I know for sure it will happen... only this catalyst could double the valuation. 2) for RGLS to restart its kidney program which was on hold. the indication is bigger than cystic fibrosis! 3) license out the various programs NASH GBM Cancer HCV 4) become clinical with its HBV program. at current valuation compared to the above you can appreciate that it can explode to say the least... but I agree it also has risks and thus it needs to be held in the appropriate QTYs...
What about neurotrope? About 80 M mcap and waiting for read out of confirmatory phase 2b. A lot of bashers on fora but I have not seen a valid argument contra. The are aiming for a drug against moderate to severe Alzheimer’s disease. Potentially the biggest commercial opportunity.
neurotrope looks more like a scam than an viable company. imho. the company has like 1 in 1000000000 chance to ever come with anything. and its valuation is many times over compared to other bios if compared value/cash if alzheimer is something you can about the companies to look into is.. PROQR ... I can go in length why. some others to mention that have some type of a chance.. RGLS.. I can go into why VCNX ... small but some chance. XENE.. the chance became bigger for it based on new research.
I agree investment in AD is extremely high risk. Everything else to date has failed, including huge projects from the main pharma companies. Reading all the ‘articles’ on the internet (e.g. seeking alpha) didn’t encourage me to buy shares either. However, I was triggered by the degree some people persevere in bashing this stock (shorters using the failure percentage of 100% in this complex indication?). In addition, the seemingly high level of science in these’ articles’ made me look into it a bit further and what I found is that 99% of all arguments used against this specific investment proposition is not accurate/valid. Most potential investors do not have sufficient scientific background to not be impressed by these hit articles. What I found is that the mechanism completely differs from what has been tested before, this tells me the history of 100% failure rate does not necessarily apply to this project. Moreover, preclinical and clinical data so far do show the principle works. The last phase 2 study did not reach statistical significance because many patients used background medication that interfered with the mechanism currently tested. The confirmatory study excluded the use of this concomitant drug. In addition, I found an article in a peer reviewed journal where I find the science behind the theory/principle is supported. (https://res.mdpi.com/ijms/ijms-20-03544/article_deploy/ijms-20-03544.pdf?filename=). Can you explain why you feel this company is scam (apart from the short-articles). I agree cash is low but what if the trial outcome is positive?
I didnt read even the short articles to figure out the company is MOST LIKELY a scam. I didnt know the company before, learned it from your question for the first time and looked it up and did a brief investigation. the company is trading on the OTCBB market which is not regulated very well therefore the company can post whatever info and pump itself up without being supervised. more so than reading the short thesis or whatever, I would be worried about who is pushing up this stock and this company.. look any drug tested has a chance to succeed .. even 1 in 10000000 is a chance. however just by briefly looking into the company I for myself think the chance is that 1 in 1000000 in not more .. but there is that chance and each one should think how to invest. Between that company and a list of others including PRQR which has the technology to one day if focused on it .. truly wipe out Alzheimers.. to invest in the others.. I think is a better choice.
Fair enough. I did not know about the limited regulation. I have seen indeed some comments that very limited data was shared about the subpopulation for which they found a decent response. I guessed they should have at least provided that information to the FDA/IRB in order to get approval for this confirmatory study. I wonder whether investigators would enroll subjects in this study when their experience in the previous study has been negative. Anyway, I agree the risk of failing is probably close to 100%. I’ll consider this investment as lost money. @Tom3: heb jij hier een mening over?
look I looked again on the company and some of the people involved in it where prosecuted in the past on scams biotech investing. with this said the element used in their drug a marine component is thought to help with Alzheimer .. the question is how much or how good they synthesized the drug and all... who knows? maybe they will succeed ... hard to say .. so maybe you will make it afterall .. its a gamble here probably would had been wise to buy it close to cash.. so about 1/3 or so current valuation to be safer .
Hunter300 schreef op 21 juli 2019 20:25 :
Fair enough. I did not know about the limited regulation. I have seen indeed some comments that very limited data was shared about the subpopulation for which they found a decent response. I guessed they should have at least provided that information to the FDA/IRB in order to get approval for this confirmatory study. I wonder whether investigators would enroll subjects in this study when their experience in the previous study has been negative. Anyway, I agree the risk of failing is probably close to 100%. I’ll consider this investment as lost money.
@Tom3: heb jij hier een mening over?
Afblijven:blogs.sciencemag.org/pipeline/archive...
joel12 schreef op 20 juli 2019 20:29 :
RGLS is getting heavily accumulated, and in the coming months its supposed to have the following catalysts
1) get 20mill from Sanofi for this continuing the licensed program. I know for sure it will happen... only this catalyst could double the valuation.
2) for RGLS to restart its kidney program which was on hold. the indication is bigger than cystic fibrosis!
3) license out the various programs
NASH
GBM Cancer
HCV
4) become clinical with its HBV program.
at current valuation compared to the above you can appreciate that it can explode to say the least... but I agree it also has risks and thus it needs to be held in the appropriate QTYs...
The stock imploded from $ 200+ in 2015 to $ 1+ now. I will check.
Tom3 schreef op 22 juli 2019 14:31 :
[...]
The stock imploded from $ 200+ in 2015 to $ 1+ now. I will check.
Vandaag mijn positie Proqr verder uitgebreid. Lijkt nu te bodemen. De tip van RGLS gelezen. Heb er een paar K gekocht. Je zou zeggen daar moet toch wat muziek in zitten ;-) Van $239 naar $1,00. Je verzint het niet....
Aantal posts per pagina:
20
50
100
Direct naar Forum
-- Selecteer een forum --
Koffiekamer
Belastingzaken
Beleggingsfondsen
Beursspel
BioPharma
Daytraders
Garantieproducten
Opties
Technische Analyse
Technische Analyse Software
Vastgoed
Warrants
10 van Tak
4Energy Invest
Aalberts
AB InBev
Abionyx Pharma
Ablynx
ABN AMRO
ABO-Group
Acacia Pharma
Accell Group
Accentis
Accsys Technologies
ACCSYS TECHNOLOGIES PLC
Ackermans & van Haaren
ADMA Biologics
Adomos
AdUX
Adyen
Aedifica
Aegon
AFC Ajax
Affimed NV
ageas
Agfa-Gevaert
Ahold
Air France - KLM
Airspray
Akka Technologies
AkzoNobel
Alfen
Allfunds Group
Allfunds Group
Almunda Professionals (vh Novisource)
Alpha Pro Tech
Alphabet Inc.
Altice
Alumexx ((Voorheen Phelix (voorheen Inverko))
AM
Amarin Corporation
Amerikaanse aandelen
AMG
AMS
Amsterdam Commodities
AMT Holding
Anavex Life Sciences Corp
Antonov
Aperam
Apollo Alternative Assets
Apple
Arcadis
Arcelor Mittal
Archos
Arcona Property Fund
arGEN-X
Aroundtown SA
Arrowhead Research
Ascencio
ASIT biotech
ASMI
ASML
ASR Nederland
ATAI Life Sciences
Atenor Group
Athlon Group
Atrium European Real Estate
Auplata
Avantium
Axsome Therapeutics
Azelis Group
Azerion
B&S Group
Baan
Ballast Nedam
BALTA GROUP N.V.
BAM Groep
Banco de Sabadell
Banimmo A
Barco
Barrick Gold
BASF SE
Basic-Fit
Basilix
Batenburg Beheer
BE Semiconductor
Beaulieulaan
Befimmo
Bekaert
Belgische aandelen
Beluga
Beter Bed
Bever
Binck
Biocartis
Biophytis
Biosynex
Biotalys
Bitcoin en andere cryptocurrencies
bluebird bio
Blydenstijn-Willink
BMW
BNP Paribas S.A.
Boeing Company
Bols (Lucas Bols N.V.)
Bone Therapeutics
Borr Drilling
Boskalis
BP PLC
bpost
Brand Funding
Brederode
Brill
Bristol-Myers Squibb
Brunel
C/Tac
Campine
Canadese aandelen
Care Property Invest
Carmila
Carrefour
Cate, ten
CECONOMY
Celyad
CFD's
CFE
CGG
Chinese aandelen
Cibox Interactive
Citygroup
Claranova
CM.com
Co.Br.Ha.
Coca-Cola European Partners
Cofinimmo
Cognosec
Colruyt
Commerzbank
Compagnie des Alpes
Compagnie du Bois Sauvage
Connect Group
Continental AG
Corbion
Core Labs
Corporate Express
Corus
Crescent (voorheen Option)
Crown van Gelder
Crucell
CTP
Curetis
CV-meter
Cyber Security 1 AB
Cybergun
D'Ieteren
D.E Master Blenders 1753
Deceuninck
Delta Lloyd
DEME
Deutsche Cannabis
DEUTSCHE POST AG
Dexia
DGB Group
DIA
Diegem Kennedy
Distri-Land Certificate
DNC
Dockwise
DPA Flex Group
Draka Holding
DSC2
DSM
Duitse aandelen
Dutch Star Companies ONE
Duurzaam Beleggen
DVRG
Ease2pay
Ebusco
Eckert-Ziegler
Econocom Group
Econosto
Edelmetalen
Ekopak
Elastic N.V.
Elia
Endemol
Energie
Energiekontor
Engie
Envipco
Erasmus Beursspel
Eriks
Esperite (voorheen Cryo Save)
EUR/USD
Eurobio
Eurocastle
Eurocommercial Properties
Euronav
Euronext
Euronext
Euronext.liffe Optiecompetitie
Europcar Mobility Group
Europlasma
EVC
EVS Broadcast Equipment
Exact
Exmar
Exor
Facebook
Fagron
Fastned
Fingerprint Cards AB
First Solar Inc
FlatexDeGiro
Floridienne
Flow Traders
Fluxys Belgium D
FNG (voorheen DICO International)
Fondsmanager Gezocht
ForFarmers
Fountain
Frans Maas
Franse aandelen
FuelCell Energy
Fugro
Futures
FX, Forex, foreign exchange market, valutamarkt
Galapagos
Gamma
Gaussin
GBL
Gemalto
General Electric
Genfit
Genmab
GeoJunxion
Getronics
Gilead Sciences
Gimv
Global Graphics
Goud
GrandVision
Great Panther Mining
Greenyard
Grolsch
Grondstoffen
Grontmij
Guru
Hagemeyer
HAL
Hamon Groep
Hedge funds: Haaien of helden?
Heijmans
Heineken
Hello Fresh
HES Beheer
Hitt
Holland Colours
Homburg Invest
Home Invest Belgium
Hoop Effektenbank, v.d.
Hunter Douglas
Hydratec Industries (v/h Nyloplast)
HyGear (NPEX effectenbeurs)
HYLORIS
Hypotheken
IBA
ICT Automatisering
Iep Invest (voorheen Punch International)
Ierse aandelen
IEX Group
IEX.nl Sparen
IMCD
Immo Moury
Immobel
Imtech
ING Groep
Innoconcepts
InPost
Insmed Incorporated (INSM)
IntegraGen
Intel
Intertrust
Intervest Offices & Warehouses
Intrasense
InVivo Therapeutics Holdings Corp (NVIV)
Isotis
JDE PEET'S
Jensen-Group
Jetix Europe
Johnson & Johnson
Just Eat Takeaway
Kardan
Kas Bank
KBC Ancora
KBC Groep
Kendrion
Keyware Technologies
Kiadis Pharma
Kinepolis Group
KKO International
Klépierre
KPN
KPNQwest
KUKA AG
La Jolla Pharmaceutical
Lavide Holding (voorheen Qurius)
LBC
LBI International
Leasinvest
Logica
Lotus Bakeries
Macintosh Retail Group
Majorel
Marel
Mastrad
Materialise NV
McGregor
MDxHealth
Mediq
Melexis
Merus Labs International
Merus NV
Microsoft
Miko
Mithra Pharmaceuticals
Montea
Moolen, van der
Mopoli
Morefield Group
Mota-Engil Africa
MotorK
Moury Construct
MTY Holdings (voorheen Alanheri)
Nationale Bank van België
Nationale Nederlanden
NBZ
Nedap
Nedfield
Nedschroef
Nedsense Enterpr
Nel ASA
Neoen SA
Neopost
Neovacs
NEPI Rockcastle
Netflix
New Sources Energy
Neways Electronics
NewTree
NexTech AR Solutions
NIBC
Nieuwe Steen Investments
Nintendo
Nokia
Nokia OYJ
Nokia Oyj
Novacyt
NOVO-NORDISK AS
NPEX
NR21
Numico
Nutreco
Nvidia
NWE Nederlandse AM Hypotheek Bank
NX Filtration
NXP Semiconductors NV
Nyrstar
Nyxoah
Océ
OCI
Octoplus
Oil States International
Onconova Therapeutics
Ontex
Onward Medical
Onxeo SA
OpenTV
OpGen
Opinies - Tilburg Trading Club
Opportunty Investment Management
Orange Belgium
Oranjewoud
Ordina Beheer
Oud ForFarmers
Oxurion (vh ThromboGenics)
P&O Nedlloyd
PAVmed
Payton Planar Magnetics
Perpetuals, Steepeners
Pershing Square Holdings Ltd
Personalized Nursing Services
Pfizer
Pharco
Pharming
Pharnext
Philips
Picanol
Pieris Pharmaceuticals
Plug Power
Politiek
Porceleyne Fles
Portugese aandelen
PostNL
Priority Telecom
Prologis Euro Prop
ProQR Therapeutics
PROSIEBENSAT.1 MEDIA SE
Prosus
Proximus
Qrf
Qualcomm
Quest For Growth
Rabobank Certificaat
Randstad
Range Beleggen
Recticel
Reed Elsevier
Reesink
Refresco Gerber
Reibel
Relief therapeutics
Renewi
Rente en valuta
Resilux
Retail Estates
RoodMicrotec
Roularta Media
Royal Bank Of Scotland
Royal Dutch Shell
RTL Group
RTL Group
S&P 500
Samas Groep
Sapec
SBM Offshore
Scandinavische (Noorse, Zweedse, Deense, Finse) aandelen
Schuitema
Seagull
Sequana Medical
Shurgard
Siemens Gamesa
Sif Holding
Signify
Simac
Sioen Industries
Sipef
Sligro Food Group
SMA Solar technology
Smartphoto Group
Smit Internationale
Snowworld
SNS Fundcoach Beleggingsfondsen Competitie
SNS Reaal
SNS Small & Midcap Competitie
Sofina
Softimat
Solocal Group
Solvac
Solvay
Sopheon
Spadel
Sparen voor later
Spectra7 Microsystems
Spotify
Spyker N.V.
Stellantis
Stellantis
Stern
Stork
Sucraf A en B
Sunrun
Super de Boer
SVK (Scheerders van Kerchove)
Syensqo
Systeem Trading
Taiwan Semiconductor Manufacturing Company (TSMC)
Technicolor
Tele Atlas
Telegraaf Media
Telenet Groep Holding
Tencent Holdings Ltd
Tesla Motors Inc.
Tessenderlo Group
Tetragon Financial Group
Teva Pharmaceutical Industries
Texaf
Theon International
TherapeuticsMD
Thunderbird Resorts
TIE
Tigenix
Tikkurila
TINC
TITAN CEMENT INTERNATIONAL
TKH Group
TMC
TNT Express
TomTom
Transocean
Trigano
Tubize
Turbo's
Twilio
UCB
Umicore
Unibail-Rodamco
Unifiedpost
Unilever
Unilever
uniQure
Unit 4 Agresso
Univar
Universal Music Group
USG People
Vallourec
Value8
Value8 Cum Pref
Van de Velde
Van Lanschot
Vastned
Vastned Retail Belgium
Vedior
VendexKBB
VEON
Vermogensbeheer
Versatel
VESTAS WIND SYSTEMS
VGP
Via Net.Works
Viohalco
Vivendi
Vivoryon Therapeutics
VNU
VolkerWessels
Volkswagen
Volta Finance
Vonovia
Vopak
Warehouses
Wave Life Sciences Ltd
Wavin
WDP
Wegener
Weibo Corp
Wereldhave
Wereldhave Belgium
Wessanen
What's Cooking
Wolters Kluwer
X-FAB
Xebec
Xeikon
Xior
Yatra Capital Limited
Zalando
Zenitel
Zénobe Gramme
Ziggo
Zilver - Silver World Spot (USD)
Premium
Word nu abonnee van IEX en krijg onbeperkt toegang tot onze (koop)tips en succesvolle modelportefeuilles. Nu 3 maanden voor slechts €19,95! Profiteer van 58% korting!
Word abonnee